Abstract 399P
Background
Due to the lack of studies on unfit patients with gastric cancer (GC) who did not receive any aggressive cancer treatment—best supportive care (BSC) cases—their long-term prognosis remains unclear, especially for those harboring potentially curable disease (clinical stage [cStage] I–III). Therefore, clinicians sometimes have trouble answering unfit patients or their caregivers when asked questions such as “How long will I live without any anticancer treatment?”. Hence, we conducted this observational study to capture the real-world data of baseline characteristics, provided supportive care, and long-term outcomes for BSC cases.
Methods
Consecutive clinical records of patients with GC diagnosed at Steel Memorial Muroran Hospital (SMMH) from January 2017 to December 2021 were collected and analyzed. We conducted this study with the approval of the Institutional Review Board of SMMH (#J230103). The primary outcome of this study is overall survival (OS).
Results
Of 481 patients diagnosed with GC, 91 (18.9%) were BSC cases; their median age was 85 (range: 46–96) years, and 75.8% were male. BSC cases showed a very high risk of receiving aggressive cancer treatment with a median Age-Adjusted Charlson Comorbidity Index score of 7 and a G-8 score of 7. The median OS for all patients was 3.9 months (95% confidence interval [CI]: 3.0–5.4). The median OS was 12.4, 8.3, and 2.5 months for cStage I, II–III, and IV, respectively. Patients with potentially curable GC (cStage I–III) had significantly longer OS than those with incurable disease (cStage IV), with a hazard ratio for death of 0.29 (95% CI: 0.18–0.47, p<0.0001). The percentage of death by GC in a total number of deaths also increased with increasing stage. Pneumonia and heart failure were the most common cause of death among cases who died other than GC. After diagnosis, cStage I patients were more likely to prefer to stay where they had lived (nursing homes or their own house), while more advanced stage patients chose hospice.
Conclusions
The median OS of BSC cases in poor general condition was ∼1 year for cStage I, 8 months for cStage II–III, and < 3 months for cStage IV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Takada: Financial Interests, Personal, Invited Speaker: Eisai, Janssen, Chugai, Ono, Otsuka, Daiichi Sankyo, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract